Biopharmaceutical Drug Design and Development

Biopharmaceutical Drug Design and Development Second Edition 1. Biotechnology: 2005 and Beyond 2. Human Genome Project 3. Bioinformatics 4. DNA Microarrays in Drug Discovery and Development 5. Microarray Technology Using Proteins, Cells, and Tissues 6. Pharmacogenetic Issues in Biopharmaceutical Drug Development 7. Transgenics 8. Therapeutic Gene Delivery 9. Stem Cells 10. Nucleic Acid Based Therapeutics 11. Therapeutic Strategies Targeting the Innate Immune Response 12. Pharmacogenetics in the Clinic 13. Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals 14. Macromolecular Drug Delivery 15. Changes in Biologic Drug Approval at FDA 16. Follow On Protein Products: The Age of Biogenerics?

[1]  Alexander Rich,et al.  FORMATION OF A THREE-STRANDED POLYNUCLEOTIDE MOLECULE , 1957 .

[2]  W. Mungall,et al.  Carbamate analogs of oligonucleotides , 1977 .

[3]  E. Stanley,et al.  Factors regulating macrophage production and growth: identity of colony- stimulating factor and macrophage growth factor , 1976, The Journal of experimental medicine.

[4]  M. Stephenson,et al.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Cech,et al.  Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena , 1982, Cell.

[6]  A. Waheed,et al.  Effect of colony stimulating factor on murine macrophages. Induction of antitumor activity. , 1982, The Journal of clinical investigation.

[7]  M. Delarue,et al.  Nucleic acid-binding molecules with high affinity and base sequence specificity: intercalating agents covalently linked to oligodeoxynucleotides. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Murakami,et al.  Characterization of sequence-specific oligodeoxyribonucleoside methylphosphonates and their interaction with rabbit globin mRNA. , 1985, Biochemistry.

[9]  F. Eckstein,et al.  Synthesis of d(GC) and d(CG) octamers containing alternating phosphorothioate linkages: effect of the phosphorothioate group on the B-Z transition. , 1985, Biochemistry.

[10]  E. Kawasaki,et al.  Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). , 1985, Science.

[11]  J. Talmadge,et al.  Immunomodulation of natural killer activity by polyribonucleotides. , 1985, Journal of biological response modifiers.

[12]  D. Melton.  Injected anti-sense RNAs specifically block messenger RNA translation in vivo. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E S Kawasaki,et al.  Quantitative hybridization-arrest of mRNA in Xenopus oocytes using single-stranded complementary DNA or oligonucleotide probes , 1985, Nucleic Acids Res..

[14]  J. Toulmé,et al.  Oligodeoxynucleotides covalently linked to intercalating agents: a new class of gene regulatory substances. , 1985, Biochimie.

[15]  P. Dervan,et al.  Sequence-specific cleavage of single-stranded DNA: oligodeoxynucleotide-EDTA X Fe(II). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Jäckle,et al.  Production of phenocopies by Krüppel antisense RNA injection into Drosophila embryos , 1985, Nature.

[17]  W. Stec,et al.  AUTOMATED SOLID-PHASE SYNTHESIS, SEPARATION, AND STEREOCHEMISTRY OF PHOSPHOROTHIOATE ANALOGS OF OLIGODEOXYRIBONUCLEOTIDES , 1985 .

[18]  T. Cech,et al.  A model for the RNA-catalyzed replication of RNA. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Nienhuis,et al.  Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Wickstrom.  Oligodeoxynucleotide stability in subcellular extracts and culture media. , 1986, Journal of biochemical and biophysical methods.

[21]  J. Toulmé,et al.  Specific inhibition of mRNA translation by complementary oligonucleotides covalently linked to intercalating agents. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Krown.  Interferons and interferon inducers in cancer treatment. , 1986, Seminars in oncology.

[23]  T. Webb,et al.  Hybridization triggered cross-linking of deoxyoligonucleotides. , 1986, Nucleic acids research.

[24]  P. Zamecnik,et al.  Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  V. Vlassov,et al.  Complementary addressed modification and cleavage of a single stranded DNA fragment with alkylating oligonucleotide derivatives. , 1986, Nucleic acids research.

[26]  T. Cech,et al.  Biological catalysis by RNA. , 1986, Annual review of biochemistry.

[27]  L. Aurelian,et al.  Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Hélène,et al.  Targeted cleavage of polynucleotides by complementary oligonucleotides covalently linked to iron-porphyrins. , 1986, Biochemistry.

[29]  N. Thuong,et al.  Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent. , 1987, Nucleic acids research.

[30]  G. Zon,et al.  Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. , 1987, Nucleic acids research.

[31]  M. Reitz,et al.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Huang,et al.  pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Kriz,et al.  Human CSF-1: molecular cloning and expression of 4-kb cDNA encoding the human urinary protein. , 1987, Science.

[34]  K. Nishikura,et al.  Antisense RNA of proto-oncogene c-fos blocks renewed growth of quiescent 3T3 cells. , 1987, Molecular and cellular biology.

[35]  C. Hélène,et al.  Oligo(alpha-deoxynucleotide)s covalently linked to intercalating agents: differential binding to ribo- and deoxyribopolynucleotides and stability towards nuclease digestion. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Eric Wickstrom,et al.  A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1 , 1987, Nature.

[37]  P. Lawrence,et al.  Phenocopies induced with antisense RNA identify the wingless gene , 1987, Cell.

[38]  K. Yokoyama,et al.  Transcriptional control of the endogenous MYC protooncogene by antisense RNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Toulmé,et al.  Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents. , 1987, Nucleic acids research.

[40]  C. Paoletti,et al.  α-DNA IV: α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding , 1987 .

[41]  J. Toulmé,et al.  An acridine-linked oligodeoxynucleotide targeted to the common 5' end of trypanosome mRNAs kills cultured parasites. , 1987, Gene.

[42]  A. Harel-Bellan,et al.  Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. , 1988, Journal of immunology.

[43]  B. Calabretta,et al.  Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. , 1988, Science.

[44]  A. Nienhuis,et al.  An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation , 1988, Molecular and cellular biology.

[45]  J. Taylor,et al.  Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage , 1988, Journal of virology.

[46]  S. H. Munroe,et al.  Antisense RNA inhibits splicing of pre‐mRNA in vitro. , 1988, The EMBO journal.

[47]  P. Miller,et al.  Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with synthetic DNA containing a promoter for T7 RNA polymerase. , 1988, Nucleic acids research.

[48]  P. Zamecnik,et al.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Zamecnik,et al.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[50]  B. Calabretta,et al.  A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. , 1988, Science.

[51]  A. Murakami,et al.  Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA. , 1988, Biochemistry.

[52]  J. Francois,et al.  Periodic cleavage of poly(dA) by oligothymidylates covalently linked to the 1,10-phenanthroline-copper complex. , 1988, Biochemistry.

[53]  D. Cerretti,et al.  Human macrophage-colony stimulating factor: alternative RNA and protein processing from a single gene. , 1988, Molecular immunology.

[54]  E. Wickstrom,et al.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  C. Stein,et al.  Oligodeoxynucleotides as inhibitors of gene expression: a review. , 1988, Cancer research.

[56]  P. Zamecnik,et al.  Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[57]  E. Kawasaki,et al.  Renaturation and Purification of Biologically Active Recombinant Human Macrophage Colony-Stimulating Factor Expressed in E. Coli , 1989, Bio/Technology.

[58]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[59]  G. Cooper,et al.  Microinjection of antisense c-mos oligonucleotides prevents meiosis II in the maturing mouse egg. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[60]  L. Aurelian,et al.  Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Toulmé,et al.  Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. , 1989, Nucleic acids research.

[62]  S. Broder,et al.  Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. , 1989, Biochemistry.

[63]  J. Summerton,et al.  Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. , 1989, Nucleic acids research.

[64]  V. Vlassov,et al.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[65]  B. Calabretta,et al.  G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. , 1989, Science.

[66]  L. Neckers,et al.  Characterization of oligonucleotide transport into living cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[67]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[68]  S. V. Vinogradov,et al.  A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus‐specific proteins in MDCK cells , 1990, FEBS letters.

[69]  Thomas,et al.  In vivo hematologic effects of recombinant human macrophage colony-stimulating factor. , 1990, Blood.

[70]  F. Ruscetti,et al.  Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide. Evidence for autocrine regulation. , 1990, Journal of immunology.

[71]  F. Szoka,et al.  Rapid nuclear accumulation of injected oligodeoxyribonucleotides. , 1990, The New biologist.

[72]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[73]  J. Toulmé,et al.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids. , 1990, Biochimica et biophysica acta.

[74]  J. Florini,et al.  Highly specific inhibition of IGF-I-stimulated differentiation by an antisense oligodeoxyribonucleotide to myogenin mRNA. No effects on other actions of IGF-T. , 1990, The Journal of biological chemistry.

[75]  Y. Cheng,et al.  Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides , 1990, Antimicrobial Agents and Chemotherapy.

[76]  J. Tschopp,et al.  Inhibition of lymphocyte mediated cytotoxicity by perforin antisense oligonucleotides. , 1990, The EMBO journal.

[77]  T. Hirano,et al.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[78]  B. Shiramizu,et al.  Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide , 1990, The Lancet.

[79]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[80]  S. Altman,et al.  External guide sequences for an RNA enzyme. , 1990, Science.

[81]  M. Cotten,et al.  Transferrin-polycation conjugates as carriers for DNA uptake into cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[82]  T. Crook,et al.  Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. , 1991, Nucleic acids research.

[83]  S. J. Flint,et al.  Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[84]  A. Carè,et al.  Antisense myb inhibition of purified erythroid progenitors in development and differentiation is linked to cycling activity and expression of DNA polymerase alpha. , 1991, Blood.

[85]  P. Iversen.  In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. , 1991, Anti-cancer drug design.

[86]  C. Burrell,et al.  Presence and distribution of human papillomavirus sense and antisense RNA transcripts in genital cancers. , 1991, The Journal of general virology.

[87]  D. L. Weeks,et al.  Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor beta 3. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[88]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[89]  S. Read,et al.  Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme , 1991, Journal of virology.

[90]  B. Calabretta,et al.  Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. , 1991, Science.

[91]  R. Wagner,et al.  Hybridization and dissociation rates of phosphodiester or modified oligodeoxynucleotides with RNA at near-physiological conditions. , 1991, Nucleic acids research.

[92]  D. Herschlag,et al.  Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[93]  J. Roth,et al.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. , 1991, Cancer research.

[94]  J. Tonkinson,et al.  Phosphorothioate oligodeoxynucleotides--anti-sense inhibitors of gene expression? , 1991, Pharmacology & therapeutics.

[95]  A. Periasamy,et al.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. , 1991, Nucleic acids research.

[96]  E. Wickstrom,et al.  Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). , 1991, Nucleic acids research.

[97]  B. Calabretta,et al.  Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides , 1992, The Journal of experimental medicine.

[98]  C. Wu,et al.  Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[99]  D. Ecker,et al.  Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[100]  S. Martino,et al.  Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. , 1992, Journal of immunotherapy.

[101]  G. T. Baxter,et al.  PKC epsilon is involved in granulocyte-macrophage colony-stimulating factor signal transduction: evidence from microphysiometry and antisense oligonucleotide experiments. , 1992, Biochemistry.

[102]  A. Rudolph,et al.  A Phase I Trial of Recombinant Human Macrophage Colony‐Stimulating Factor by Rapid Intravenous Infusion in Patients with Refractory Malignancy , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[103]  D. Melton,et al.  Specificity of antisense oligonucleotides in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[104]  D. Longo,et al.  Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. , 1992, Cancer research.

[105]  H. Itoh,et al.  Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide. , 1992, Biochemical and biophysical research communications.

[106]  M. Heinrich,et al.  Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides. , 1992, Blood.

[107]  John M. Burke,et al.  Optimization of an anti-HIV hairpin ribozyme by in vitro selection. , 1993, The Journal of biological chemistry.

[108]  S. Lederman,et al.  Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. , 1993, Antisense research and development.

[109]  L. Neckers,et al.  Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[110]  O. Yamada,et al.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[111]  A. Dritschilo,et al.  Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. , 1993, Biochemical and biophysical research communications.

[112]  R. Erickson,et al.  The use of antisense approaches to study development. , 1993, Developmental genetics.

[113]  D. Scott,et al.  Antisense oligodeoxynucleotides to the blk tyrosine kinase prevent anti-mu-chain-mediated growth inhibition and apoptosis in a B-cell lymphoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[114]  T. McElwain,et al.  Ribozyme cleaves rex/tax mRNA and inhibits bovine leukemia virus expression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[115]  A. Nicolin,et al.  Antiproliferative effect of DNA polymerase alpha antisense oligodeoxynucleotides on breast cancer cells. , 1993, Experimental cell research.

[116]  S. Rotenberg,et al.  Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. , 1993, Biochemistry.

[117]  John Calvin Reed,et al.  Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. , 1993, Antisense research and development.

[118]  Catalytic RNA: structure and mechanism. , 1993, Biochemical Society transactions.

[119]  L. Griffin,et al.  The discovery and characterization of a novel nucleotide-based thrombin inhibitor. , 1993, Gene.

[120]  D. Praseuth,et al.  Unexpected effect of an anti-human immunodeficiency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript. , 1993, Antisense research and development.

[121]  T. Billiar,et al.  Antisense oligodeoxynucleotide to inducible nitric oxide synthase inhibits nitric oxide synthesis in rat pulmonary artery smooth muscle cells in culture. , 1993, Surgery.

[122]  D F Hoth,et al.  Present status and future prospects for HIV therapies. , 1993, Science.

[123]  M. Volm,et al.  Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. , 1993, Oncology.

[124]  E. Uhlmann,et al.  Oligonucleotide analogs containing dephospho-internucleoside linkages. , 1993, Methods in molecular biology.

[125]  J. Lisziewicz,et al.  Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element , 1993, Journal of virology.

[126]  P. Iversen,et al.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. , 1993, Antisense research and development.

[127]  C. Benz,et al.  In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation. , 1994, Nucleic acids research.

[128]  T. Dorai,et al.  Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. , 1994, Cancer research.

[129]  B. Wold,et al.  Phosphorothioate oligonucleotide-directed triple helix formation. , 1994, Biochemistry.

[130]  V. A. Flørenes,et al.  Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. , 1994, Cancer research.

[131]  Wei-xing Li,et al.  A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. , 1994, Blood.

[132]  G. R. Dodge,et al.  Transcatheter Delivery of c‐myc Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury , 1994, Circulation.

[133]  C. Wu,et al.  Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. , 1994, Nucleic acids research.

[134]  M. Marahiel,et al.  The major cold shock protein of Bacillus subtilis CspB binds with high affinity to the ATTGG‐ and CCAAT sequences in single stranded oligonucleotides , 1994, FEBS letters.

[135]  John Calvin Reed,et al.  Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. , 1994, Antisense research and development.

[136]  R. Brousseau,et al.  Specific targeting of antisense oligonucleotides to neutrophils. , 1994, Antisense research and development.

[137]  P. Zamecnik,et al.  Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[138]  D. Ecker,et al.  Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[139]  T. Cech,et al.  Ribozyme-mediated repair of defective mRNA by targeted trans-splicing , 1994, Nature.

[140]  K. Motoyoshi.  Macrophage colony-stimulating factor for cancer therapy. , 1994, Oncology.

[141]  C. Hunt,et al.  Characterization of the oligodeoxynucleotide-mediated inhibition of interferon-gamma-induced major histocompatibility complex class I and intercellular adhesion molecule-1. , 1994, The Journal of biological chemistry.

[142]  A. Volodin,et al.  Efficient interaction of recA protein with fluorescent dye‐labeled oligonucleotides , 1994, FEBS letters.

[143]  T. Chung,et al.  Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[144]  B. Redman,et al.  Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[145]  D. Curiel.  High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. , 1994, Natural immunity.

[146]  R. Levitz,et al.  In vivo decay kinetic parameters of hammerhead ribozymes. , 1994, Nucleic acids research.

[147]  L. Chrisey,et al.  Non-sequence-specific antimalarial activity of oligodeoxynucleotides. , 1994, Molecular and biochemical parasitology.

[148]  J A Cavagnaro,et al.  Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. , 1994, Antisense research and development.

[149]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. , 1994, Blood.

[150]  S. Agrawal,et al.  Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. , 1994, Antisense research and development.

[151]  J. Cognet,et al.  Solution structure of an oncogenic DNA duplex, the K-ras gene and the sequence containing a central C.A or A.G mismatch as a function of pH: nuclear magnetic resonance and molecular dynamics studies. , 1995, Journal of molecular biology.

[152]  A. Karpeisky,et al.  Chemical Modification of Hammerhead Ribozymes , 1995, The Journal of Biological Chemistry.

[153]  R. Diasio,et al.  Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. , 1995, Biochemical pharmacology.

[154]  F. Keith,et al.  Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. , 1995, Leukemia.

[155]  J. Weaver,et al.  Transdermal transport of DNA antisense oligonucleotides by electroporation. , 1995, Biochemical and biophysical research communications.

[156]  R. Diasio,et al.  Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. , 1995, Biochemical pharmacology.

[157]  T. Azuma.  Ribozyme-mediated cleavage of the bcr-abl transcript , 1995 .

[158]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.

[159]  C. Stein,et al.  Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[160]  E. Kyle,et al.  Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. , 1995, Antisense research and development.

[161]  R. Maranhão,et al.  Synthetic Oligonucleotide Does Not Bind to Lipid Emulsion Resembling Low‐Density Lipoprotein a , 1995, Annals of the New York Academy of Sciences.

[162]  P. D. Cook,et al.  2'-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. , 1996, Journal of medicinal chemistry.

[163]  D. Ma,et al.  Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. , 1996, Leukemia research.

[164]  Y. Rojanasakul,et al.  Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. , 1996, Biochimica et biophysica acta.

[165]  R. Gaynor,et al.  A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription , 1996, Journal of virology.

[166]  F. Wong-Staal,et al.  Ex vivo transduction and expansion of CD4+ lymphocytes from HIV + donors: prelude to a ribozyme gene therapy trial. , 1996, Gene Therapy.

[167]  T. Abe,et al.  Contiguous Four‐guanosine Sequence in c‐myc Antisense Phosphorothioate Oligonucleotides Inhibits Cell Growth on Human Lung Cancer Cells: Possible Involvement of Cell Adhesion Inhibition , 1997, Japanese journal of cancer research : Gann.

[168]  D. Samuels,et al.  Oligonucleotide-mediated genetic transformation of Borrelia burgdorferi. , 1997, Microbiology.

[169]  P. Nicklin,et al.  Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. , 1997, Biochemical pharmacology.

[170]  S. Wu‐Pong,et al.  Oligonucleotide biological activity: relationship to the cell cycle and nuclear transport. , 1997, Biology of the cell.

[171]  W. Stec,et al.  Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease. , 1997, Antisense & nucleic acid drug development.

[172]  M. Perälä-Heape,et al.  Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. , 1997, Biochimica et biophysica acta.

[173]  R. Figlin,et al.  Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. , 1997, The New England journal of medicine.

[174]  G. Chaudhuri.  Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. , 1997, Biochemical pharmacology.

[175]  G. Favre,et al.  Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV). , 1997, Biochimica et biophysica acta.